The patients were imaged for gozetotide [68Ga]-PSMA-11-PET/CT using Biograph TruePoint PET-CT (Siemens, Erlangen, Germany). Patients were injected with [68Ga]-PSMA-11; average activity was 350 MBq (range 210–400 MBq). Imaging was performed in two phases: early pelvic body imaging at an average time of 11 ± 4 min and late, whole-body imaging at an average time of 60 ± 5 min.
The whole body was imaged from the calvarium to the mid-thighs, as described in [18 (link)]. Then, (Na18F)-PET/CT imaging was performed at 60 min (range 58–76 min) as a whole-body imaging (from the calvarium to the tips of toes), with an average activity of 222 MBq (range 192 to 251 MBq).
Image data sets were 68Ga-PSMA-11-PET/CT with nominal administered activity 280 MBq, uptake time 60 min, and scan range from the apex to the mid-thighs. Image data sets also included NaF PET/CT with nominal administered activity 220 MBq, uptake time 60 min, and whole-body scan range. Both PET/CT scans were performed on the same PET/CT scanner within a day of each other. A total of 26 patients were analyzed in this study—14 patients in the M group and 12 patients in the N group.
Both [68Ga]-PSMA-11 and Na18F received special permission for clinical use from the Finnish Medical Evaluation Agency (FiMEA). These tracers were produced by MAP Medical Technologies Oy, Tikkakoski, Finland.
The whole body was imaged from the calvarium to the mid-thighs, as described in [18 (link)]. Then, (Na18F)-PET/CT imaging was performed at 60 min (range 58–76 min) as a whole-body imaging (from the calvarium to the tips of toes), with an average activity of 222 MBq (range 192 to 251 MBq).
Image data sets were 68Ga-PSMA-11-PET/CT with nominal administered activity 280 MBq, uptake time 60 min, and scan range from the apex to the mid-thighs. Image data sets also included NaF PET/CT with nominal administered activity 220 MBq, uptake time 60 min, and whole-body scan range. Both PET/CT scans were performed on the same PET/CT scanner within a day of each other. A total of 26 patients were analyzed in this study—14 patients in the M group and 12 patients in the N group.
Both [68Ga]-PSMA-11 and Na18F received special permission for clinical use from the Finnish Medical Evaluation Agency (FiMEA). These tracers were produced by MAP Medical Technologies Oy, Tikkakoski, Finland.
Free full text: Click here
